#ASCO24 ASCO #CRCsm TRANSMET - Chemo +/- OLTx in unresectable liver metastases, OS Dr Rene Adam 🇫🇷 📌<65y, no BRAFmut, CEA <80 📌 n=94, 15% R-sided, median 20 tumours, 60% 3+L of chemo. 36/47 went on to OLtx ⭐️ 5yr OS ITT 57% vs 13%, HR0.37 (73% vs 9% per-protocol) 📌 42%

Orchestra: debulking debunked! 🇳🇱#ASCO24 - No benefit of debulking in 1st line pts with multi-organ metastatic CRC - median OS 27.5 vs 30 months; p=0.23

Tumor debulking to first-line CTx for patients with multiorgan metastatic colorectal cancer #ASCO24 🔎ORCHESTRA phase III, 382 pts 👉10 yr accrual 👉mPFS: 10.4 vs 10.5 mo 👉mOS: 27.5 vs 30 mo, HR: 0.88 🧐Tumor debulking does not make sense ESMO - Eur. Oncology

ORCHESTRA 🎻 trial shows no benefit and increased morbidity to tumor debulking compared to SOC for #mCRC with multifocal visceral disease #ASCO24 OHSU Department of Surgery OHSU Knight Cancer Institute Divya Sood OncoAlert

Neoadjuvant pembrolizumab stratified to TMB for high risk stage 2 or stage 3 MSI-high CRC #ASCO24 🔎NEOPRISM-CRC, 32 pts 👉only 1 TMB-low 👉62% rT1a/b 👉pCR: 59% 👉No relapse 🧐safe & effective, translational program awaited ESMO - Eur. Oncology

🧭Treatment of metastatic CRC #ASCO24 ASCO

#CercekPlot Andrea Cercek achieved 42 out of 42 COMPLETE clinical responses in MMRd - #rectalcancer - 100%!! #ASCO24 ASCO Memorial Sloan Kettering Cancer Center

Ecstatic and proud to share the NICHE-2 results, now published in NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. John Haanen nej.md/3Ku4X0H

Intensive locoregional therapy before Liver Transplantation ... : Liver Transplantation journals-lww-com.ezproxy.uio.no/lt/abstract/99…

Clinical impact of ctDNA to track minimal residual disease in CRC. Hopes and limitations ESMO Open doi.org/10.1016/j.esmo… 👏very comprehensive review 👉undeniable prognostic role, but still some work to do to intergrate as tool for optimal personalized treatment strategies

TRANSMET study update #ESMOGI24: liver transplantation for irresectable CRC liver mets ESMO - Eur. Oncology #ESMOAmbassadors

📢Hepatopancreaticobiliary-NET abstracts in #ESMO24 ESMO - Eur. Oncology ➡️HCC ✅LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study ✅LBA38 - Iparomlimab and

ITT outcomes of pts with HCC receiving immunotherapy before liver transplant Journal of Hepatology doi.org/10.1016/j.jhep… 🔎🇺🇸VITALITY study 👉86 pts 👉75.6% downstaged 👉36% LTx 👉3-year ITT OS 71.1% 👉 7 rejections, 1 graft lost 🧐More evidence to support ICI before LTx ESMO - Eur. Oncology

NICHE2 3-year disease-free survival in patients receiving nivo ipi before surgery of their localised dMMR colon cancer: 100%!!! Myriam Chalabi #ESMO24

Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: #ESMO24 🔎3-year disease-free survival from NICHE-2 👉💯% DFS 👉all MRD pts cleared ctDNA 🧐Impressive results, ctDNA may be helpful to select for organ preservation ESMO - Eur. Oncology #ESMOAmbassadors

#ESMO24 ESMO - Eur. Oncology Excellent discussion by Jenny Seligmann contextualizing IO in early stage #CRCsm NICHE-2 and NICHE-3 Myriam Chalabi & IMHOTEP 📌non-randomized datasets, robust and meaningful efficacy 📌higher pCR with more IO ✅is this data enough to change practice? YES ⛔️is

#ESMO24 Boarded and on my way home BCN-YVR ✈️🇨🇦 🙏 ESMO - Eur. Oncology Andres Cervantes Rebecca Dent & Jenny Seligmann Sarah Derks for a 🤩 #GIcancers track 🤔 my top 3 #ESMO24 GI picks: ⭐️ PODIUM303-InterAACT2 ⭐️ NICHE-2 ⭐️ TOPGEAR-2 ➡️ all academic/cooperative trials 🙌

New The Lancet - Adam et al - Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet trial) thelancet.com/journals/lance… #CRCSM #LiverTwitter

🏔️ A new milestone has been reached! 🔵 Out now in The Lancet Transmet Trial 💥 Liver Transplantation + chemotherapy superior to chemo alone in permanently unresectable CRLM 📈 5-year overall survival 56·6% vs. 12.6% A new era has begun?! 🧐 sciencedirect.com/science/articl…

Delighted to hear about Oslounivsykehus trials #cholangiocarcinoma #TESLA 🚙 #TOMCAT🐱 moving to the 🪡 at #NordicHPB 🇳🇴 🇸🇪 🇩🇰 🇫🇮 Kudos 👏🏽 to Sheraz Yaqub and Kristoffer Lassen Cholangiocarcinoma Foundation ENS-CCA AMMF IHPBA #transplantoncology #hopedealer #endcancer